SYRS - Syros Pharmaceuticals, Inc.
IEX Last Trade
0.198
-0.013 -6.414%
Share volume: 12,903
Last Updated: Fri 27 Dec 2024 08:28:55 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$0.21
-0.01
-6.03%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-14 | 2023-03-02 | 2023-05-10 | 2023-08-08 | 2023-11-14 | 2024-03-27 | 2024-05-14 | 2024-07-31 | |
| Assets | |||||||||
| Total Assets | 284.725 M | 244.486 M | 205.323 M | 180.982 M | 147.795 M | 168.174 M | 134.728 M | 106.722 M | |
| Current Assets | 252.305 M | 211.392 M | 173.644 M | 152.630 M | 122.515 M | 144.980 M | 112.202 M | 84.921 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 7.824 M | 9.088 M | 7.841 M | 6.892 M | 8.631 M | 5.454 M | 3.898 M | 5.957 M | |
| Short Term Investments | 7.824 M | 9.088 M | 7.841 M | 6.892 M | 8.631 M | 5.454 M | 3.898 M | 5.957 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 1.756 M | 1.665 M | 0.000 | 0.000 | 0.000 | |
| Current Cash | 244.481 M | 202.304 M | 165.803 M | 143.982 M | 112.219 M | 139.526 M | 108.304 M | 78.964 M | |
| Total Non-current Assets | 32.420 M | 33.094 M | 31.679 M | 28.352 M | 25.280 M | 23.194 M | 22.526 M | 21.801 M | |
| Property Plant Equipment | 12.062 M | 11.353 M | 10.950 M | 10.299 M | 7.614 M | 7.298 M | 6.964 M | 6.633 M | |
| Other Assets | 3.808 M | 5.424 M | 4.657 M | 2.236 M | 2.116 M | 1.592 M | 1.550 M | 1.460 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 284.725 M | 244.486 M | 205.323 M | 180.982 M | 147.795 M | 168.174 M | 134.728 M | 106.722 M | |
| Total liabilities | 155.554 M | 116.750 M | 98.570 M | 107.743 M | 111.493 M | 151.512 M | 119.671 M | 113.074 M | |
| Total current liabilities | 38.424 M | 30.778 M | 23.551 M | 28.375 M | 28.394 M | 36.681 M | 37.303 M | 24.521 M | |
| Accounts Payable | 13.017 M | 6.411 M | 2.795 M | 6.693 M | 2.855 M | 11.544 M | 11.346 M | 7.469 M | |
| Other liabilities | 55.228 M | 24.472 M | 15.607 M | 18.712 M | 24.549 M | 61.747 M | 34.773 M | 30.387 M | |
| Current long term debt | 137.000 K | 65.000 K | 1.679 M | 8.000 K | 1.670 M | 6.667 M | 11.667 M | 0.000 | |
| Long term debt | 40.517 M | 40.649 M | 39.117 M | 40.930 M | 39.406 M | 34.556 M | 29.708 M | 40.934 M | |
| Other liabilities | 55.228 M | 24.472 M | 15.607 M | 18.712 M | 24.549 M | 61.747 M | 34.773 M | 30.387 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 129.171 M | 127.736 M | 106.753 M | 73.239 M | 36.302 M | 16.662 M | 15.057 M | -6.352 M | |
| Common stock | 9.417 M | 28.422 M | 27.842 M | 27.913 M | 27.991 M | 29.557 M | 38.978 M | 39.269 M | |
| Retained earnings | -553.459 M | -558.233 M | -582.022 M | -618.280 M | -658.423 M | -722.807 M | -726.515 M | -749.842 M |